The Atlas Genetics io® CT/NG test, designed to be performed in the clinic or decentralised laboratory whilst the patient waits, can enable immediate treatment of positive patients, removing the need for presumptive treatment, improving compliance and reducing loss to follow-up. Rapid test results provided by the io® CT/NG assist in lowering the risk of onward transmission of these STIs and the potential for sequelae in infected patients, whilst reducing clinical pathway costs and improving the patient experience. The use of two discrete NG targets provides simultaneous confirmatory testing for greater accuracy and confidence.
The Atlas Genetics io® MSTI+ (Multi-STI+) test is a combined test for four common sexually transmitted diseases, Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis and Mycoplasma genitalium, infections with similar symptoms but requiring different treatments. The io® MSTI+ Cartridge is being developed to enable the detection and identification of these four STI pathogens in around 30 minutes from a single patient specimen, expediting targeted therapy, reducing inappropriate and presumptive treatment, improving antibiotic stewardship.
The io® MG+R test simultaneously detects for the presence of Mycoplasma genitalium and mutations associated with macrolide resistance. This can enable immediate and effective treatment of Mycoplasma genitalium positive patients with the appropriate antibiotic, to ensure better antibiotic stewardship and lower treatment costs for many patients.